RT Journal Article
SR Electronic
T1 Defining and phenotyping gastric abnormalities in long-term type 1 diabetes using body surface gastric mapping
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.10.22278649
DO 10.1101/2022.08.10.22278649
A1 Xu, William
A1 Gharibans, Armen A.
A1 Calder, Stefan
A1 Schamberg, Gabriel
A1 Walters, Anthony
A1 Jang, Jia
A1 Varghese, Chris
A1 Carson, Daniel
A1 Daker, Charlotte
A1 Waite, Stephen
A1 Andrews, Christopher N
A1 Cundy, Tim
A1 O’Grady, Gregory
YR 2022
UL http://medrxiv.org/content/early/2022/08/11/2022.08.10.22278649.abstract
AB Objective To define phenotypes of gastric myoelectrical abnormalities and relation to symptoms in people with longstanding T1D, compared to matched healthy controls, using a novel non-invasive body surface gastric mapping (BSGM) device.Research design and methods BSGM was performed on people with T1D of >10 years duration and matched controls, employing Gastric Alimetry (Alimetry, New Zealand), comprising a high-resolution 64-channel array, validated symptom logging App, and wearable reader.Results 32 people with T1D were recruited (15 with a high symptom burden), and 32 controls. Those with symptoms showed more unstable gastric myoelectrical activity, (Gastric Alimetry Rhythm Index 0.39 vs 0.51, p=0.017; and lower average spatial covariance 0.48 vs 0.51, p=0.009) compared with controls. Those with T1D and symptoms also had higher prevalence of peripheral neuropathy (67% vs 6%, p=0.001), anxiety/depression diagnoses (27% vs 0%, p=0.001), and mean HbA1c levels (76 vs 56 mmol/mol, p<0.001). BSGM defined distinct phenotypes in participants including those with markedly unstable gastric rhythms (4/32, 12.5%), and abnormally high gastric frequencies (10/32, 31%). Deviation in gastric frequency was positively correlated with symptoms of bloating, upper gut pain, nausea and vomiting, and fullness and early satiation (r>0.35, p<0.05)Conclusion Gastroduodenal symptoms in people with longstanding T1D correlate with gastric myoelectrical abnormalities on BSGM evaluation, in addition to glycemic control, psychological comorbidities, and peripheral neuropathy. BSGM using the Gastric Alimetry device identified a range of myoelectrical phenotypes, representing both myogenic and neurogenic mechanisms, which represent targets for diagnosis, monitoring and therapy.Competing Interest StatementProfessor Greg O'Grady, holds grants and intellectual property in the field of gastrointestinal electrophysiology and is a co-founder and Director in University spin-out companies: The Insides Company Ltd and Alimetry Ltd. Dr Gharibans holds grants and intellectual property in the field of gastrointestinal electrophysiology and is a co-founder and Director of Alimetry Ltd. Dr Calder, Dr Schamberg, Dr Waite, Dr Daker, and Prof. Andrews are members of Alimetry Ltd. The remaining authors have no conflicts of interest to declare.Funding StatementThis project was supported by the Health Research Council of New Zealand, the NIH (R56 DK126935) and the John Mitchell Crouch Fellowship from the Royal Australasian College of Surgeons.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Auckland Health Research Ethical Committee of the University of Auckland (AHREC: 1130) and the University of Calgary ethics committee of the University of Calgary (ID: REB19-1925) gave ethical approval for this work All patients provided informed written consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors